Lates News

China CITIC International released a research report stating that WuXi AppTec (02359) had a strong performance in the first half of the year with robust growth in revenue and net profit. The profit margin expanded, and the TIDES business performed exceptionally well. At the same time, the resilience of the chemical business helped offset the weakness in the clinical CRO and testing business. Management raised their revenue guidance for 2025 to 42.5 billion to 43.5 billion yuan, with a 13% to 17% growth in continued operating business. Capital expenditure will remain at 7 billion to 8 billion yuan. China CITIC International raised their profit forecast for WuXi AppTec for the next two years by 15% and 22%, and raised the target price from 81 Hong Kong dollars to 122 Hong Kong dollars, maintaining a "buy" rating.